The success of cancer therapies based on allogeneic hematopoietic stem cell transplant relies on the ability to separate graft-versus-host disease (GvHD) from graft-versus-tumor (GVT) responses. Controlling donor T cell migration into peripheral tissues is a viable option to limit unwanted tissue damage, but a lack of specific targets limits progress on this front. Here, we show that the adaptor protein CrkL, but not the closely related family members CrkI or CrkII, is a crucial regulator of T cell migration. In vitro, CrkL-deficient T cells fail to polymerize actin in response to the integrin ligand ICAM-1, resulting in defective migration. Using a mouse model of GvHD/GVT, we found that while CrkL-deficient T cells can efficiently eliminate hematopoietic tumors they are unable to migrate into inflamed organs, such as the liver and small intestine, and thus do not cause GvHD. These results suggest a specific role for CrkL in trafficking to peripheral organs but not the lymphatic system. In line with this, we found that although CrkL-deficient T cells could clear hematopoietic tumors, they failed to clear the same tumor growing subcutaneously, highlighting the role of CrkL in controlling T cell migration into peripheral tissues. Our results define a unique role for CrkL in controlling T cell migration, and suggest that CrkL function could be therapeutically targeted to enhance the efficacy of immunotherapies involving allogeneic donor cells.
INTRODUCTION
T cell migration out of the vasculature into peripheral tissue is a key control point in the inflammatory response. Although trafficking to tissues is required for protective immunity, uncontrolled T cell infiltration into tissue can result in exacerbated inflammation and tissue damage. T cell recruitment is highly regulated by the local endothelial cells which, in response to pro-inflammatory cues, up-regulate molecules such as chemokines and adhesion receptors. These molecules promote T cell adhesion to the endothelial monolayer, and guide migration through the monolayer into the tissue 1 . The endothelial ligands ICAM-1 and VCAM-1 are recognized by the T cell integrins LFA-1 and VLA-4, respectively, which mediate firm adhesion to the vascular wall and subsequent migration into inflamed tissue 1, 2 . In addition to acting as adhesion receptors, integrins also initiate downstream signaling events that are important for T cell migration. For instance, ligation of LFA-1
immediately results in T cell polarization, actin polymerization, and migration, all of which are necessary for crossing the endothelial barrier 3, 4, 5, 6, 7 . Integrin blocking antibodies have been used successfully to treat multiple sclerosis and other inflammatory diseases, but this approach interferes with a broad range of responses.
Disruption of signaling events downstream of engaged integrins could yield more context-specific therapies, but to develop such strategies, a better understanding of the relevant signaling pathways is required.
We recently identified the CT10 Regulator of Kinase (Crk) family of adapter proteins as crucial intermediaries that link LFA-1 engagement to actin responses and migration in T cells 7 . Activated T cells lacking Crk proteins fail to polymerize actin downstream of LFA-1, and migrate slower and less directionally than their WT counterparts 7 . Importantly, these mutant T cells also have defects in crossing endothelial monolayers in vitro, and they fail to traffic to sites of inflammation in vivo 8 . Additionally, using a clinically relevant mouse model of graft-versus-host disease / graft-versus-leukemia (GvHD/GVL), we showed that T cells lacking Crk proteins can efficiently clear tumor cells but cause little-to-no GvHD pathology 8 . Consistent with the view that Crk proteins mediate integrin-dependent trafficking in a tissue-specific manner, we found that Crk deficient T cells could not migrate to the target GvHD organs liver and small intestine (SI), although they trafficked efficiently to the secondary lymphoid organs spleen and lymph nodes. These findings identify
Crk proteins as potential targets for tissue-selective disruption of integrin-dependent inflammatory responses.
Development of Crk proteins as therapeutic targets requires addressing redundancy among family members. The Crk family consists of three isoforms transcribed from two loci. CrkI and CrkII are transcribed from the crk locus, while the paralog CrkL is transcribed from the crkl locus. These proteins are composed of a single N-terminal SH2 domain, followed by either two consecutive SH3 domains (CrkII and CrkL), or a single SH3 domain (CrkI) 9 . The Crk proteins are widely expressed across tissues and have many biological functions, all of which stem from their role as adaptor proteins that coordinate signaling complexes downstream of cell surface receptors 9, 10 . Crk proteins are particularly important for adhesion and migration 11 . They have been shown to localize to adhesion sites and regulate the stability of these structures in non-hematopoietic cells 12, 13, 14, 15 , and alterations in their expression is associated with invasive potential in several tumors 16, 17, 18 . Crk family members share many of the same binding partners, and they have been shown to have overlapping functions in some processes 15, 19, 20 . On the other hand, there are clear instances (most notably during development) where the Crk proteins have non-overlapping roles, showing that in some instances they have evolved separate functions 21, 22 . All of our previous work defining the role of Crk proteins in T cell migration was performed using a mouse floxed for both the crk and crkl loci and crossed with a CD4-cre mouse, resulting in T cells devoid for all three family members (herein referred to as DKO 
RESULTS

CrkL is needed for T cell spreading and migration in response to the integrin ligand ICAM-1
We showed previously that T cells lacking all Crk family members exhibit defects in integrin-dependent migration and in vivo trafficking 7, 8 . To ask if this aspect of Crk protein function depends on a single protein isoform or if there is functional redundancy among family members, we used mice that are floxed for either the crk or the crkL locus, crossed with CD4-Cre mice to specific delete these loci in T cells. The resulting T cells are lacking either CrkI/II or CrkL (Fig 1A) . We first tested the ability of these T cells to polymerize actin and migrate in response to surface-presented integrin ligands in vitro. Rested CD4 + T cell blasts were prepared as described in Materials and Methods, and then allowed to interact with ICAM-1 coated surfaces, fixed, and labelled with phalloidin to visualize F-actin. As shown previously 4, 5, 7 , WT T cells adhered tightly to the surfaces, and formed a polarized morphology characteristic of cells migrating on ICAM-1 (Fig 1B) . These WT cells showed strong actin polymerization, especially at the leading edge (Fig 1B) . T cells lacking CrkI/II were indistinguishable from the WT cells. In contrast, DKO and CrkL KO T cells failed to spread, and lacked a clear F-actin-rich leading edge (Fig 1B) . Quantitation of the total F-actin signal confirmed that DKO and CrkL KO T cells responding to ICAM-1 contained significantly less F-actin than WT or CrkI/II KO T cells (Fig 1C) . To determine if the defects in actin responses result in altered migration, we imaged T cells migrating on ICAM-1 coated surfaces and tracked cell movement. DKO and CrkL KO T cells migrated significantly slower than WT or CrkI/II KO cells (Fig 1D) . As we showed previously for DKO T cells 7 , loss of a clear actin-rich leading edge also resulted in reduced directional persistence in CrkL KO T cells (data not shown). Together, these data
show that the two products of the Crk locus, CrkI and CrkII, are dispensable for actin polymerization and migration downstream of integrin engagement. The CrkL protein is the relevant family member controlling these events in T cells.
T cells lacking CrkL clear hematopoietic tumors but fail to traffic to target GvHD organs
To ask if CrkL is also the critical Crk family member responsible for T cell migration in vivo, we utilized a graft-versus-host / graft-versus-tumor mouse model (GvHD/GVT). In this model, GvHD occurs in a subset of organs and involves early migration of alloreactive T cells into these organs followed by T cell expansion and later tissue destruction (Fig 2A-D) . As we showed previously 8 , DKO CD8 + T cells did not cause GvHD, but still efficiently cleared the tumor cells, resulting in healthy mice throughout the course of the experiment. CrkL KO CD8 + T cells recapitulated the DKO phenotype, while CrkI/II KO CD8 + T cells had a phenotype indistinguishable from the WT. This pattern was observed for all disease metrics, including overall survival (Fig 2A-D) .
Based on the failure of CrkL KO T cells to migrate normally in vitro, we reasoned that CrkL KO T cells do not cause GvHD because of their inability to traffic to target GvHD organs. However, because the GvHD/GVT experiments are take place over the course of several weeks, it is difficult to establish a causative role for T cell migration in initiating the inflammatory response. We therefore set up a short-term competitive experiment to examine the role of Crk proteins in T cell migration into target GvHD organs. (Fig 3A-B) . This was also true for CrkI/II KO T cells, indicating that Crk I and Crk II are dispensable for T cell migration in vivo. However, when DKO or CrkL KO T cells were used, these T cells had a significant defect in migration to the liver and the small intestine compared to their CD45.1 + WT counterparts. Importantly, migration into the spleen was largely normal, indicating that DKO and CrkL KO T cells can still traffic efficiently to lymphoid organs (Fig 3A-B) . Taken together with the data in Figures 1 and 2 , these results demonstrate that CrkL is the relevant Crk family protein controlling T cell migration both in vitro and in vivo, and highlights the importance of CrkL-dependent T cell trafficking during inflammation and GvHD.
CrkL KO T cells fail to eliminate a sub-cutaneous tumor
The trafficking studies above suggest that the ability of CrkL KO T cells to clear lymphoma cells while inducing minimal GvHD pathology stems from their ability to migrate efficiently to lymphoid tissues where the tumor resides, but not to GvHD target organs. If so, one would predict that if the tumor were located in a peripheral tissue outside of the lymphatic system, CrkL KO T cells would not be able to access and kill the tumor. To test this, we set up a GvHD/GVT experiment similar to that in Figure 2 , except that the A20 tumor cells were injected subcutaneously as opposed to intravenously. As shown in Figure 4 , both WT and CrkI/II KO T cells efficiently cleared the subcutaneous tumor, but these animals succumbed to GvHD. In contrast, DKO and CrkL KO T cells were unable to clear the subcutaneous tumor and these recipients were sacrificed due to the resulting tumor pathology (Fig 4A-D) . Together, these data indicate that deletion of CrkL in T cells can separate GvHD from GVT effects, but only for tumors that reside in the circulation and in secondary lymphoid organs (e.g. hematologic malignancies). More broadly, these data provide strong evidence that the CrkL controls T cell entry into inflamed tissues, and that disruption of CrkL function can be used to perturb this trafficking, while preserving trafficking to lymphoid organs.
DISCUSSION
We showed previously that T cells lacking all Crk family proteins exhibit defective migration into inflamed tissue in vivo, and an inability to carry out transendothelial migration (TEM) in vitro 8 . Interestingly, this in vitro phenotype could be rescued by overexpression of any Crk family member 8 We show that CrkL KO T cells fail to enter inflamed tissues and subcutaneous tumors, but they efficiently access lymphoid tissues. The selective requirement for CrkL in entering inflamed tissue likely reflects the requisite role of CrkL in regulating actin dynamics downstream of integrin engagement. T cells actively migrate on inflamed postcapillary venules and make numerous actin-dependent invadopodia-like protrusions to push their way through the endothelial monolayer 6, 29, 30 . Therefore, the ability of the T cell to polymerize actin, migrate, and probe the endothelium may be defining factors for the ability to cross postcapillary venules. The preferential ability of CrkL KO T cells to access lymph nodes is likely to be attributable to differences in endothelial barriers. To access lymph nodes, T cells must cross high endothelial venules, specialized structures that create large pockets to fully engulf transmigrating T cells, efficiently escorting them across the barrier 31 . This process may be much less demanding with respect to force generation by the T cell actin cytoskeleton. Going forward, it will be interesting to identify CrkL binding partners and other signaling molecules needed for integrin-dependent actin responses and passage into inflamed tissues. Targeting these molecules could be used to more finely control T cell trafficking in the treatment of inflammatory diseases and for the design of next-generation adoptive T cell therapies
MATERIALS AND METHODS
Antibodies and Reagents
Anti-CD3 (2C11) and anti-CD28 (PV1) were from BioXCell. Anti-CrkL (SC-319) was from Santa Cruz. Anti- a spinning disk confocal system (Ultraview ERS6; PerkinElmer). Four z-planes spanning a total of 0.75µm were collected at the cell-surface interface with an Orca Flash 4.0 camera (Hamamatsu). Image analysis of the rendered stacks was conducted using Velocity v6.3 software. Cells were identified using the "Find Objects"
command, using a low threshold on the actin channel, and total phalloidin staining was quantified per cell based on integrated pixel intensity. 
Quantification of
Western Blotting
Proteins were separated using NuPAGE 4-12% BisTris gels, transferred to nitrocellulose membranes (0.45µm, BioRad) and blocked using LI-COR blocking buffer diluted 1:1 with PBS for 1 hr at RT. Primary antibodies were mixed in Tris-buffered saline, 0.1% tween-20 (TBST) with 2% BSA and membranes were probed overnight at 4°C. After washing, membranes were incubated with fluorescent secondary antibodies and imaged using a LI-COR Odyssey system.
Graft-versus-Host Disease (GvHD) and Graft-versus-Tumor (GVT) studies
Lethally irradiated BALB/c mice (800 cGy) mice were injcted intravenously with 5x10 6 T cell-depleted bone marrow (TCDBM) cells with or without 2x10 6 FACS-sorted CD8 + T cells from either WT, DKO, CrkI/II KO or CrkL KO mice. For GVT experiments, A20 B lymphoma cells transduced with luciferase were cultured as described previously 41 , and 1x10 5 A20 cells were injected into the mice at the same time with TCDBM and CD8 + T cells. For skin tumor experiments, the A20 cells were injected subcutaneously 1x10 6 . Mice were evaluated twice a week from the time of tumor injection by bioluminescence imaging using the IVIS 200
Imaging System (Xenogen) as previously described 42 . Clinical presentation of the mice was assessed 2-3 times per week using a scoring system that sums changes in 5 clinical parameters: weight loss, posture, activity, fur texture, and skin integrity 43 . Mice were euthanized when their weight dropped to < 30% of their initial body weight.
For cell sorting to obtain purified CD8+ T cells, T cells were purified with anti-CD8 magnetic beads using MACS columns (Miltenyi Biotec, Auburn, CA) prior to cell surface staining. FACS sorting was performed with a FACSAria cell sorter (BD Biosciences). FACS-sorted populations were typically of >95% purity.
In vivo migration assays
Lethally irradiated BALB/c mice were injected intravenously with 5x10 6 WT T cell-depleted bone marrow 
Statistical analysis
Statistics were calculated using GraphPad Prism 8. Student's t-test was used to compare two groups; when more than two groups were compared, a one-way ANOVA was performed using multiple comparisons with a Tukey correction. *p<0.05; **p<0.01; ***p<0.001 
